Efficacy and Cost-Efficacy of Biologic Therapies for Moderate to Severe Psoriasis : A Meta-Analysis and Cost-Efficacy Analysis Using the Intention-to-Treat Principle

Abstract EN

Background.

Compared to conventional therapies, biologics are more effective but expensive in treating psoriasis.

Objective.

To evaluate the efficacy and cost-efficacy of biologic therapies for psoriasis.

Methods.

We conducted a meta-analysis to calculate the efficacy of etanercept, adalimumab, infliximab, and ustekinumab for at least 75% reduction in the Psoriasis Area and Severity Index score (PASI 75) and Physician’s Global Assessment clear/minimal (PGA 0/1).

The cost-efficacy was assessed by calculating the incremental cost-effectiveness ratio (ICER) per subject achieving PASI 75 and PGA 0/1.

Results.

The incremental efficacy regarding PASI 75 was 55% (95% confidence interval (95% CI) 38%–72%), 63% (95% CI 59%–67%), 71% (95% CI 67%–76%), 67% (95% CI 62%–73%), and 72% (95% CI 68%–75%) for etanercept, adalimumab, infliximab, and ustekinumab 45 mg and 90 mg, respectively.

The corresponding 6-month ICER regarding PASI 75 was $32,643 (best case $24,936; worst case $47,246), $21,315 (best case $20,043; worst case $22,760), $27,782 (best case $25,954; worst case $29,440), $25,055 (best case $22,996; worst case $27,075), and $46,630 (best case $44,765; worst case $49,373), respectively.

The results regarding PGA 0/1 were similar.

Conclusions.

Infliximab and ustekinumab 90 mg had the highest efficacy.

Meanwhile, adalimumab had the best cost-efficacy, followed by ustekinumab 45 mg and infliximab.